Takeda, Twi move to dismiss US antitrust claims over Dexilant
( October 2, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceutical and Twi Pharmaceuticals moved to dismiss US claims that they entered into an illegal reverse payment agreement to restrain competition in the US market for Dexilant and its generic equivalents, arguing that the claims came too late. “Contrary to the claim that defendants engaged in fraudulent concealment, plaintiffs plead that defendants publicly announced the settlement in 2015—indeed, it is those public announcements upon which plaintiffs now base their claims. And, plaintiffs plead no overt acts by defendants since 2015 that amounted to a continuing violation of the antitrust laws sufficient to restart the statute of limitation,” they said.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.